Table 3.

Abnormal clinical signs during study phase (days 0–7)^*

Abnormal clinical sign	Oclacitinib-treated dogs [n = 216; n (%)]†	Placebo-treated dogs [n = 220; n (%)]
Diarrhoea	5 (2.3)	2 (0.9)
Vomiting	5 (2.3)	4 (1.8)
Lethargy	4 (1.8)	3 (1.4)
Anorexia	3 (1.4)	0 (0.0)
Polydipsia	3 (1.4)	0 (0.0)

^*Seen in >1% of dogs.

^†Number and percentage are given on a per animal basis.